Position in EXEL
as of Mar 31, 2026
· filed May 1, 2026
Position Value
$25,734
-$564 QoQ
Shares Held
600
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Anchor Investment Management, LLC holds $1,529,617 across 11 Biotechnology names. EXEL ranks #7 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,819 | $932,722 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
391 | $174,597 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
4,700 | $156,134 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
184 | $142,165 | |
| 5 | INCY |
Incyte Corp
|
500 | $47,060 | |
| 6 | ONC |
BeOne Medicines Ltd.
|
108 | $32,072 | |
| 7 | EXEL |
Exelixis, Inc.
This page
|
600 | $25,734 | |
| 8 | ARGX |
Argenx SE
|
20 | $14,605 |
All Filings in EXEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $25,734 | 600 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $26,298 | 600 | Shares | Sole | 2026-02-26 | |
| 2025-09-30 | $24,780 | 600 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $4,408 | 100 | Shares | Sole | 2025-08-19 | |
| No filing history on record for this holder in this stock. | ||||||